Actively Recruiting
First-in-Human Trial Evaluating Safety and Preliminary Antitumour Effects of ODM-216 in Adults with Advanced Solid Tumours
Led by Orion Corporation, Orion Pharma · Updated on 2026-09-24
195
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ODM-216, a drug being studied in a Phase 12, open-label, first-in-human trial involving participants with advanced solid tumors. The study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of ODM-216 in patients whose cancers are resistant or intolerant to standard treatments. This trial is sponsored by Orion Corporation, Orion Pharma. Participants receive ODM-216 as the experimental treatment during the trial. The study follows a sequential model, and participants must undergo baseline tumor biopsies for assessment. Treatment effects and safety will be closely monitored throughout the study, with special attention to dose-limiting toxicities, adverse events, and clinical laboratory abnormalities including electrocardiogram ECG results. The treatment is administered under medical supervision as described in the trial protocol. During the study, participants undergo regular evaluations including tumor measurements per RECIST v1.1 criteria and safety assessments over a period of up to 22 months. Researchers will monitor laboratory tests, ECGs, and adverse events for up to 12 and 22 months to understand the impact of ODM-216. The total duration of participation depends on individual outcomes and treatment tolerance, with continuous observation of treatment-emergent effects and tumor response.
CONDITIONS
Brief Title
Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer
Research Team
C
Clinical Study Director Clinical Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here